<a href=Novartis” height=”227″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/Main/Novartis.jpg” style=”padding: 10px” width=”303″ />

Australia-based CSL has signed an agreement to acquire the global influenza vaccine business from Swiss drug-maker Novartis, for $275m.

CSL will include the acquired business in its subsidiary bioCSL.

CSL CEO Paul Perreault said: "The Novartis influenza vaccine business provides bioCSL with a global leadership position in an attractive sector we understand intimately.

"It will transform bioCSL by giving it first class facilities and global scale as well as product and geographic diversity."

With manufacturing facilities in the US, UK, Germany and Australia, the combined influenza business is said to become the second largest company in the $4bn global influenza vaccine industry.

According to CSL, the combined business is expected to report $1bn sales per annum in the coming three to five years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Novartis CEO Joseph Jimenez said: "In CSL, we have found not only an owner for the influenza business that shares our commitment to protecting public health, but also a strong growth platform for the business and our associates."

Subject to regulatory approval, the transaction is expected to be completed in the second half of 2015.

Novartis will operate the influenza vaccines business until the transaction with CSL is completed. It will be reported with the non-influenza business, which is divested to GlaxoSmithKline (GSK).

"According to CSL, the combined business is expected to report $1bn sales per annum in the coming three to five years."

In April, Novartis signed an agreement with GSK to exchange certain assets in key segments.

As part of the deal, Novartis agreed to acquire GSK oncology products, and to divest its vaccines, excluding influenza to GSK.

The transaction with GSK is expected to be completed in the first half of 2015.

Both companies agreed to establish a joint venture by combining their consumer divisions, in a bid to expand healthcare business.

Image: Novartis AG headquarters in Basel. Photo: courtesy of Andrew Hecht.